Why Trump’s threatened pharmaceutical tariffs would be unlikely to lower prices in the U.S.
U.S. President Donald Trump has repeatedly mentioned pharmaceuticals as another industry that could be targeted by tariffs, ...
Vertex Pharmaceuticals price target raised to $540 from $522 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $540 from $522 and keeps a Buy rating on the ...
Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?
Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) ...
stocknews3d
3 Genomic Stocks at the Forefront of Precision Medicine
Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...
BioSpace3d
Cystic Fibrosis Biotech Sionna Announces $150M IPO
The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...
Vertex Pharmaceuticals Unusual Options Activity
Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex ...
3 Magnificent Stocks to Buy and Hold Forever
Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...
FierceBiotech3d
Sionna eyes up $156M IPO to fund cystic fibrosis trials
Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into ...
Vertex Pharmaceuticals (VRTX) Set for Painless Gains After FDA Approval
Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...
Scotiabank Issues Positive Forecast for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price hoisted by Scotiabank from $430.00 to $433.00 in a research note released on Friday morning,Benzinga reports. The brokerage ...